Six Predictions for H2 2026: Grading Ourselves on Retatrutide, AI Telehealth, and the FDA Advisory
Putting Stakes in the Ground
The State of Peptides 2026 (H1 Edition) closes with something unusual for an industry report: falsifiable predictions with assigned confidence levels. Rather than hedge with "trends to watch" language, the report lists six specific, checkable calls that will be graded in the next edition — treating the peptide market as a system predictable enough to test hypotheses against.
The approach mirrors the forecasting discipline practiced in other high-uncertainty domains: make the claim explicit, assign a probability, wait for the data. For an industry moving as quickly as peptides in 2026, six months is enough time to prove or disprove most of these theses. Here's what the report is betting on for the second half of the year, and why each prediction matters beyond its own outcome.
High-Confidence Calls: Retatrutide, AI Telehealth, and Sourcing Standards
Three predictions carry a "high confidence" tag, meaning the report authors estimate better than 70% odds of occurring before year-end.
Retatrutide posts a positive Phase 3 interim readout in 2026. The triple-agonist GLP-1/GIP/glucagon candidate from Eli Lilly has already posted Phase 2 data strong enough — roughly 24% weight loss at 48 weeks — to make partial Phase 3 results highly likely by Q4. If it hits, retatrutide cements the next generation of obesity pharmacotherapy and likely accelerates FDA filing timelines into 2027. If it misses, the entire "beyond dual-agonist" narrative takes a credibility hit.
At least two AI-native, solo-operator telehealth companies launch publicly at a ≥$10M run rate. This is the Medvi test: can the $401 million valuation achieved by a one-person AI-driven peptide telehealth operation be replicated? The report sees multiple operators already in-market attempting the same playbook — AI handling patient intake, prescribing logic, and fulfillment coordination with minimal human overhead. Two public launches at eight-figure scale would confirm the model is exportable, not a one-off. It would also confirm that the operational floor for peptide distribution has permanently collapsed.
Sourcing standards keep rising — more emphasis on verified vendors and published testing. Quality differentiation is accelerating, not stabilizing. The gap between suppliers publishing third-party HPLC certificates and those operating on trust is widening, and the report expects that gap to become even more visible in H2 as educated buyers demand proof and platforms like peptidealliance.io standardize verification expectations. High confidence here reflects an observable trend already in motion, not a directional bet.
Medium-Confidence Calls: The FDA Advisory and Compounding Demand
Two predictions carry medium confidence, roughly 50–60% odds.
The July FDA advisory produces clarity — a status-quo or "more rulemaking needed" outcome — rather than a sweeping reclassification. The advisory committee reviewing BPC-157, TB-500, MOTS-c, and three other research peptides is scheduled for July 2026. The report's base case: the committee asks for more data or punts to further rulemaking, rather than immediately reclassifying the peptides as drugs requiring NDAs. The prediction is hedged because genuine regulatory interest exists, and the FDA has shown willingness to act quickly on compounding when it perceives safety risk. But dramatic policy shifts at advisory committees remain rare.
Compounded-GLP-1 demand is shown to have transitioned largely into branded and legitimate channels as the market matures. This is the "gray-market contraction" thesis: as Ozempic and Mounjaro supply stabilizes and as telehealth platforms scale legitimate compounded prescriptions through licensed pharmacies, the underground and dubious-sourcing layer of the GLP-1 market shrinks. Medium confidence reflects limited public data on the gray market's actual size, making the claim harder to verify cleanly.
The GLP-1 Everywhere Prediction
One final call sits at high confidence but operates on a different timescale: The GLP-1 food-demand story shows up in more consumer-goods earnings commentary, not less. Walmart, PepsiCo, General Mills, and Nestlé have all referenced GLP-1-driven appetite suppression in investor calls during H1 2026. The report predicts this language becomes more frequent and specific in H2, not a one-quarter curiosity. High confidence here reflects the fact that GLP-1 prescriptions are still growing and their second-order effects on food purchasing are still materializing in the data.
Why This Matters
Predictions like these serve two purposes. First, they force the report authors to stake reputational capital on specific outcomes, making the analysis falsifiable and the next edition accountable. Second, they surface the assumptions embedded in the report's broader thesis — that peptides are moving from gray-market novelty to regulated, capital-backed, clinically serious category.
If most of these predictions hit, that thesis strengthens. If most miss, the industry is moving in a direction the data didn't anticipate, and the H2 2026 edition will have to explain why. Either way, the discipline of making checkable calls in a volatile market produces better analysis than hedging every sentence.
Read the full set of predictions, confidence levels, and supporting data in The State of Peptides 2026 (H1 Edition) — the site's flagship report tracking the peptide industry's evolution in real time.
This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare provider before starting any peptide protocol.